Effect of N_Acetylcysteine on Liver Functions in Donors in Living Liver Transplantation

A

Ain Shams University

Status and phase

Completed
Phase 2
Phase 1

Conditions

Liver Transplant; Complications

Treatments

Drug: Placebo
Drug: N-Acetylecysteine

Study type

Interventional

Funder types

Other

Identifiers

NCT03634566
R 10/2018

Details and patient eligibility

About

our practice for the past 10 years we have noticed a transitional impairment of liver function (elevated liver enzymes, total and direct bilirubin, and elevated serum lactate levels) following donors' liver resection. Several drugs have been investigation on liver regeneration , proven benefit of N-Acetylcysteine (NAC) on rats with steatohpatitis

Enrollment

50 patients

Sex

All

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • ASA I or II donors
  • healthy adult

Exclusion criteria

  • kidney, liver disease
  • any contraindications for organ donation

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

50 participants in 2 patient groups, including a placebo group

NAC group
Active Comparator group
Description:
Group NC received NAC 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
Treatment:
Drug: N-Acetylecysteine
Control group
Placebo Comparator group
Description:
Group C (Control group) will receive ringer acetate continuous infusion at same rate for 2 days.
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems